CIMETIDINE IN THE TREATMENT OF ACTIVE DUODENAL AND PREPYLORIC ULCERS

Abstract 44 patients with endoscopically confirmed duodenal (36) or prepyloric (8) ulcers have received in a double-blind trial either the histamine H 2 -receptor antagonist cimetidine (30 patients) or placebo (14 patients) for six weeks. At three weeks 67% of patients treated with cimetidine and 17% of those receiving placebo had endoscopically healed ulcers (χ 2 =8.49; P 2 =11.11; P